Intermediate Risk Prostate Cancer Clinical Trials

6 recruitingLast updated: June 26, 2026

There are 6 actively recruiting intermediate risk prostate cancer clinical trials across 5 countries. Studies span Not Applicable, Phase 2. Top locations include Toronto, Ontario, Canada, Boston, Massachusetts, United States, Copenhagen, Denmark. Updated daily from ClinicalTrials.gov.


Intermediate Risk Prostate Cancer Trials at a Glance

6 actively recruiting trials for intermediate risk prostate cancer are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Toronto, Boston, and Copenhagen. Lead sponsors running intermediate risk prostate cancer studies include University Health Network, Toronto, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, and Martin T. King, MD, PhD.

Browse intermediate risk prostate cancer trials by phase

Treatments under study

About Intermediate Risk Prostate Cancer Clinical Trials

Looking for clinical trials for Intermediate Risk Prostate Cancer? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Intermediate Risk Prostate Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Intermediate Risk Prostate Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Not Applicable

MRI Guided Focal Laser Ablation of Prostate Cancer

Prostate CancerLow and Intermediate Risk Prostate Cancer
University Health Network, Toronto102 enrolled1 locationNCT03650595
Recruiting
Phase 2

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

Prostate CancerHigh-risk Prostate CancerIntermediate Risk Prostate Cancer
Martin T. King, MD, PhD23 enrolled4 locationsNCT07393867
Recruiting
Not Applicable

Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions

Locally Advanced Prostate CancerProstate Cancer Patients Undergoing External Radiation and Seed ImplantationHigh Risk Localised Prostate Carcinoma+1 more
Rigshospitalet, Denmark1,016 enrolled3 locationsNCT07343349
Recruiting
Not Applicable

The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance

Localized Prostate CancerLow-Risk Prostate CancerIntermediate Risk Prostate Cancer
NHS Lothian100 enrolled1 locationNCT06117059
Recruiting
Not Applicable

Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & Effectiveness

Prostate Cancer (Adenocarcinoma)Low and Intermediate Risk Prostate Cancer
University Health Network, Toronto7 enrolled1 locationNCT07339943
Recruiting

Using genetic information to assist treatment decision making for people on active surveillance following diagnosis with favourable intermediate-risk prostate cancer

Intermediate Risk Prostate Cancer
Australian and New Zealand Urogenital and Prostate Cancer Trials Group1,950 enrolled1 locationACTRN12624000905561